Cellectis CLLS
NASDAQ CLLS
$1.43 +0.03 (+2.14%)
At close: Oct 2, 2026 · 4:00 PM EDT

Cellectis (CLLS) Change in Accured Expenses (2021 - 2022)

Updated

Cellectis (CLLS) posted Change in Accured Expenses of $37,000 for Q1 2022, down 77.8% from $167,000 a year earlier.

Analysis

Cellectis (CLLS) Change in Accured Expenses (2021 - 2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Accured Exp. (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 2.96 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 1.20 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -251.00 Mn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 901.00 Mn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 338.00 Mn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -
10 Cellectis 143.49 Mn -609.91 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 37,000.00
Mar 31, 2021 167,000.00
API Access

Cellectis Change in Accured Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-accured-expenses&ticker=CLLS&period=max&api_key=YOUR_API_KEY